Fresenius SE & Co KGaA (FRE.DE) Q1 2026 Earnings Call Transcript
Bullish Medical - Specialties 32.01B Germany
There is no Profile data available for FRE.SG.
Fresenius delivered solid 2025 results with double-digit core EPS growth and strong cash generation, while outlining an innovation-led path (REJUVENATE) toward 2026 with targeted margin expansion, a higher capex pace, and a 5% dividend increase amid macro volatility and tariff uncertainties.
⭐ Key Highlights
2025 performance and 2026 plan
Fresenius delivered strong 2025 execution with 7% organic revenue growth and 6% EBIT growth at constant currency, while guidance for 2026 focuses on accelerated organic growth and margin expansion.
REJUVENATE progress and new guidance shift
REJUVENATE continues to drive margin expansion and capital discipline, with the group moving to Core EPS guidance and targeting 17-19% EBIT margin for Kabi and ongoing margin improvements across platforms.
Balance sheet and shareholder return
Net debt/EBITDA improved to 2.7x in 2025, with a 5% dividend increase to EUR 1.05 per share for 2025 and a commitment to strong cash conversion and deleveraging.
Biopharma and MedTech momentum
Biopharma growth remained robust (coupled to Tyenne, Otulfi, and denosumab biosimilars) with notable EBIT margin resilience; Ivenix is a key MedTech growth driver entering 2026.
Helios and Kabi trajectory with challenges
Kabi delivered strong Q4 but long-term margin progression depends on volume-led growth and supply chain execution; Helios faces ongoing margin normalization and needs to accelerate efficiency, with 2026 guidance reflecting price dynamics and DRG changes.
✔Positive Signals
- 2025 core EPS grew double-digit for the second straight year, outpacing revenue growth
- Debt reduction and stronger balance sheet with net debt/EBITDA at 2.7x
- Dividend increased by 5% to EUR 1.05 per share
- Strong Q4 performance: 9% organic revenue growth and 16% core EPS growth
- Biopharma momentum and Ivenix contributing to MedTech growth in 2026
✖Negative Signals
- Helios underperformance relative to Kabi and ongoing margin improvement needs
- Tariff volatility and US regulatory developments add uncertainty to guidance
- Operational leverage and corporate cost line may offset some margin gains
- DRG reforms and price changes in Germany could impact Helios margins
- Potential near-term Q1 softness in Biopharma if Biopharma growth decelerates post-strong Q4
📊Financial Results
- 2025: 7% organic revenue growth; 6% EBIT growth at constant currency
- Q4 2025: 9% organic growth; 13% EBIT growth at constant currency; 16% core EPS growth
- Operating cash flow in 2025 exceeded EUR 1.3 billion; net debt/EBITDA 2.7x
- 12-month free cash flow includes FMC divestment and pro rata sale (~EUR 560 million)
- Group margin and EPS gains driven by Kabi, with Helios delivering margin expansion but needing further progress
🔮Future Guidance
- 2026: 4-7% organic revenue growth; Core EPS growth 5-10% (CER); group EBIT margin around 11.5%
- Kabi 16.5-17% EBIT margin; Helios 10-10.5% EBIT margin; Pharma around 20% margin
- Capex outlook at ~5.5% of revenues in 2026 (up from 4.4% in 2025)
- Dividend guidance at EUR 1.05 for 2025 (up 5%), with leverage target 2.5-3x
- FX impact expected to subtract around 1% from revenue, EBIT, and Core EPS if December 31 spot rates hold
💡Interesting Insights
- Core EPS now used for group guidance, reflecting a shift to a more sustainable profitability metric
- REJUVENATE aims to unlock value through adjacencies and platform scaling, not just internal efficiency
- Casiopea digital health ecosystem and AI diagnostics showcased as a differentiator in care provision
Detailed Analysis
AI-generated summary of Fresenius SE & Co KGaA earnings call transcript.
In 2025 Fresenius posted solid organic growth across its segments, highlighted by 7% group revenue growth and 6% EBIT growth at constant currency, with core EPS rising double digits for the second year in a row and a robust balance sheet (net debt/EBITDA at 2.7x). The company advanced its REJUVENATE program, launching new products and expanding biosimilars, nutrition, and MedTech platforms, including Ivenix, while strengthening the US domestic supply chain for essential medicines. 2025 free cash flow benefited from asset divestments and a FMC-related pro rata sale, supporting deleveraging and a 5% dividend increase to EUR 1.05 per share. For 2026, Fresenius guides 4-7% organic revenue growth and 5-10% Core EPS growth (CER), with Kabi targeting 16.5-17% EBIT margin and Helios 10-10.5%, implying an overall group margin around 11.5%. They also signal higher CapEx (about 5.5% of revenue) and continued focus on capital allocation, R&D, and digital transformation, while acknowledging tariff and regulatory uncertainties stemming from recent US rulings and DRG changes. The management stressed that resilience, innovation, and a more mature operating model under REJUVENATE underpin the growth trajectory, though Helios needs to accelerate sustainable operational excellence to meet expectations.
Get Real-Time Earnings Call Alerts for Fresenius SE & Co KGaA
Create a free MarketAlerts account to add FRE.DE to your watchlist and receive instant AI-powered alerts when new earnings call transcripts, insider trades, and technical signals are detected.
Other MarketAlerts Features
